Journal of Clinical Oncology
Articles in this Issue
A cohort study of concurrent chemoradiotherapy combined with or without immune checkpoint inhibitor in locally advanced esophageal cancer.
312 Background: The survival benefit and optimal timing of immune checkpoint inhibitors (ICIs) combined with definitive ch...
Proteogenomic interrogation of gastrointestinal neuroendocrine carcinoma.
639 Background: Gastrointestinal neuroendocrine carcinoma (GI-NEC) is a rare and aggressive cancer with limited therapeuti...
JAGUAR (JACCRO PM-01): A prospective study to evaluate the clinical utility of serial comprehensive genomic profiling testing using circulating tumor DNA in patients with metastatic colorectal cancer.
TPS244 Background: Comprehensive genomic profiling (CGP) using next-generation sequencing is recommended in metastatic col...
Everolimus or lanreotide: Who is the true winner for GI-NETs?
636 Background: Everolimus and lanreotide are established therapies for gastrointestinal neuroendocrine tumors (GI-NETs),...
Skeletal muscle loss during neoadjuvant chemotherapy as a predictor of major postoperative complications in esophageal cancer patients.
310 Background: Preoperative malnutrition and sarcopenia are known risk factors for postoperative complications. Nutrition...
A potential new biomarker for enhanced molecular imaging of colorectal cancer.
232 Background: More than 40% of patients with localized colorectal cancer (CRC) will experience recurrence after completi...
Hepatocellular carcinoma second-line systemic therapies.
544 Background: In the United States in 2024, there were 29,365 new cases of hepatocellular carcinoma (HCC). Historically,...
Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation.
693 Background: The purpose of this study was to develop and implement a procedure to reduce severe pain from pancreatic c...
Artificial intelligence–enabled precision oncology in early-onset colorectal cancer: Molecular characterization using spatial proteomics, spatial transcriptomics, multi-omics, microbiome, social determinants, and clinical data.
192 Background: Early-onset colorectal cancer (EOCRC; <50 years) is increasing at an alarming rate and disproportionate...
The interplay of HLA diversity and copy loss, T-cell profiles, and immunotherapy efficacy in colorectal adenocarcinoma.
196 Background: HLA Class I (HLA-I) proteins present antigens to CD8+ T-cells to facilitate antitumor responses. The impac...
Unmasking the lethality: National mortality patterns of pancreatic cancer in the U.S.
680 Background: Pancreatic cancer continues to be a highly deadly disease, with survival rates improving more slowly than...
Biliary tract carcinoma: Real-world evidence in a developing country.
494 Background: Biliary-tract-carcinoma (BTC) is rare, with limited data in Colombia. To fill this void, this study descri...
ALTOPANC: Local ablative therapies in oligometastatic pancreatic adenocarcinoma—A bi-national French-Belgian retrospective study.
728 Background: Oligometastatic disease (OMD) in pancreatic ductal adenocarcinoma (PDAC) is an emerging clinical entity. T...
Alliance A022104/NRG-GI010, a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC): The Janus Rectal Cancer trial.
TPS279 Background: A total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of...
Retreatment patterns and outcomes in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with [ <sup>177</sup> Lu]Lu-DOTA-TATE ( <sup>177</sup> Lu-DOTATATE): A PRIME real-world study.
625 Background: Available treatment options for advanced GEP-NETs include surgery, somatostatin analogs (SSA), chemotherap...
CRITICS-II: A multicenter randomized phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
283 Background: Radical surgery remains the cornerstone of cure in non-metastatic resectable gastric cancer, but survival...
Majority of people, minority of places: The people–place gap in US biliary tract cancer trial access across social vulnerability strata.
486 Background: Biliary tract cancers (BTC) are uncommon malignancies with poor outcomes. Clinical trial access is central...
Survival outcomes and treatment patterns by specific metastatic sites in stage IV colon cancer: A national registry analysis.
82 Background: Existing studies of metastatic colon cancer often group patients with more than one metastatic site into a...
Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase II trial (SYLT-023).
377 Background: A Phase I study demonstrated that tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxalipl...
Pathological complete response after systemic conversion therapy and curative resection in initially unresectable hepatocellular carcinoma: Feasibility of a tumor-free for drug-free strategy.
496 Background: The outcomes and optimal postoperative management of patients with initially unresectable hepatocellular c...
Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status.
76 Background: Immune checkpoint blockers (ICBs) are front-line therapy for mismatch repair-deficient (dMMR)/microsatellit...
Liposomal irinotecan, carboplatin or oxaliplatin (LyRICX) with or without nivolumab in the first-line treatment of metastatic or irresectable esophagogastric adenocarcinoma: A randomized phase 2 study.
LBA287 Background: Oxaliplatin-based regimens are standard of care for metastatic/irresectable esophagogastric cancer, but...
Antibiotic therapy and outcomes with gemcitabine, cisplatin and durvalumab in advanced cholangiocarcinoma: A large real-world analysis.
815 Background: Antibiotic exposure within close proximity to the initiation of systemic chemoimmunotherapy often occurs i...
Transcriptomic analysis of patients with colorectal cancer in Ireland.
191 Background: Early onset colorectal cancer (EOCRC), diagnosed in patients under 50 years, is rising globally. The under...
Real-world outcomes of durvalumab or pembrolizumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (BTC).
546 Background: Durvalumab or pembrolizumab combined with GemCis are established first-line treatment for patients with un...